Constellation Brands’ shares tumble as higher costs hit beer supply chain

Constellation Brands’ shares tumble as higher costs hit beer supply chain


A worker stacks cases of Constellation Brands’ Corona beer for delivery at the Euclid Beverage LLC warehouse in Peru, Illinois.

Daniel Acker | Bloomberg | Getty Images

Shares of Constellation Brands fell Thursday after the wine, beer and spirits company reported ongoing supply chain costs that offset sales growth in its beer category.

The stock closed down nearly 9% Thursday.

The company, which makes Corona beer and Svedka vodka, also lowered its earnings out look for the fiscal year. Constellation said it now projects earnings of $11 to $11.20 per share for the year, down from its previous guidance of $11.20 to $11.60 per share. 

For the three months ended Nov. 30, Constellation’s beer segment posted year-over-year net sales growth of 8%, driven by continued growth of its Modelo Especial and Modelo Chelada brands.

However, the company cited higher costs from raw materials, packaging and logistics, brewery expansions and marketing, which offset beer sales growth.

In a conference call with analysts Tuesday morning, Chief Executive Officer Bill Newlands added that a “recent series of headwinds” hit the company’s beer business towards the end of its fiscal third quarter, including poor weather and economic conditions in California.

Its operating margin in the beer business decreased during the quarter to 37.5% from 41.3% a year earlier.

The company said it plans to continue price increases on its beer products to match higher operating costs plaguing its supply chain.

For its third quarter, Constellation’s over net income fell to $467.7 million, or $2.52 a share, from $470.8 million, or $2.48 a share, from a year ago.



Source

FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More